Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
Applied DNA Sciences (NASDAQ:APDN) will present its Linea™ IVT platform at the 4th Annual mRNA-based Therapeutics Summit in Boston, July 29-31, 2024. The platform combines an enzymatically produced DNA template with a next-generation RNA polymerase to manufacture mRNA with reduced double-stranded RNA (dsRNA) contamination. This addresses a key industry challenge without sacrificing yields.
The poster, titled 'Reduction of dsRNA Contamination in High-Yield mRNA Production,' will be presented on July 30. Clay Shorrock, executive director of business development at LineaRx, highlighted that dsRNA reduction is a top priority for therapy developers and CDMOs to ensure efficient mRNA expression, reduce immunogenicity risks, and meet regulatory compliance. The Linea IVT platform offers a fully enzymatic solution that could support the development of transformative mRNA-based medicines, including therapeutics, vaccines, and personalized therapies.
Applied DNA Sciences (NASDAQ:APDN) presenterà la sua piattaforma Linea™ IVT al 4° Summit annuale sulle terapie basate su mRNA che si terrà a Boston dal 29 al 31 luglio 2024. La piattaforma combina un modello di DNA prodotto enzymaticamente con una polimerasi RNA di nuova generazione per produrre mRNA con una ridotta contaminazione da RNA a doppio filamento (dsRNA). Questo affronta una sfida chiave del settore senza sacrificare i rendimenti.
Il poster, intitolato 'Riduzione della contaminazione da dsRNA nella produzione di mRNA ad alto rendimento', sarà presentato il 30 luglio. Clay Shorrock, direttore esecutivo dello sviluppo commerciale di LineaRx, ha sottolineato che la riduzione del dsRNA è una priorità assoluta per gli sviluppatori di terapie e per i CDMO per garantire un'espressione efficiente dell'mRNA, ridurre i rischi di immunogenicità e soddisfare la conformità normativa. La piattaforma Linea IVT offre una soluzione completamente enzimatica che potrebbe supportare lo sviluppo di farmaci trasformativi basati su mRNA, comprese terapie, vaccini e terapie personalizzate.
Applied DNA Sciences (NASDAQ:APDN) presentará su plataforma Linea™ IVT en la 4ª Cumbre Anual sobre Terapias Basadas en mRNA en Boston, del 29 al 31 de julio de 2024. La plataforma combina una plantilla de ADN producida enzimáticamente con una polimerasa de RNA de nueva generación para fabricar mRNA con una contaminación reducida de RNA de cadena doble (dsRNA). Esto aborda un desafío clave de la industria sin sacrificar los rendimientos.
El póster, titulado 'Reducción de la Contaminación de dsRNA en la Producción de mRNA de Alto Rendimiento', se presentará el 30 de julio. Clay Shorrock, director ejecutivo de desarrollo empresarial en LineaRx, destacó que la reducción de dsRNA es una prioridad principal para los desarrolladores de terapias y los CDMO para garantizar una expresión eficiente de mRNA, reducir los riesgos de inmunogenicidad y cumplir con la normativa. La plataforma Linea IVT ofrece una solución completamente enzimática que podría apoyar el desarrollo de medicamentos transformativos basados en mRNA, incluidas terapias, vacunas y terapias personalizadas.
Applied DNA Sciences (NASDAQ:APDN)는 2024년 7월 29일부터 31일까지 보스턴에서 개최되는 제4회 mRNA 기반 치료제 정상 회의에서 Linea™ IVT 플랫폼을 발표할 예정입니다. 이 플랫폼은 효소적으로 생산된 DNA 템플릿과 차세대 RNA 중합효소를 결합하여 이중 가닥 RNA (dsRNA) 오염을 줄인 mRNA를 제조합니다. 이는 수익을 희생하지 않으면서 업계의 주요 과제를 해결합니다.
'고수익 mRNA 생산에서 dsRNA 오염 감소'라는 제목의 포스터가 7월 30일에 발표될 예정입니다. LineaRx의 비즈니스 개발 전무이사인 Clay Shorrock은 dsRNA 감소가 치료제 개발자와 CDMO에게 최고의 우선사항이라고 강조했습니다. 이는 효율적인 mRNA 발현을 보장하고 면역원성 위험을 줄이며 규제 준수를 달성하기 위함입니다. Linea IVT 플랫폼은 완전한 효소적 솔루션을 제공하여 치료제, 백신 및 개인 맞춤 치료제를 포함한 혁신적인 mRNA 기반 의약품 개발을 지원할 수 있습니다.
Applied DNA Sciences (NASDAQ:APDN) présentera sa plateforme Linea™ IVT lors du 4ème Sommet Annuel sur les Thérapeutiques Basées sur l'mRNA à Boston, du 29 au 31 juillet 2024. La plateforme combine un modèle d'ADN produit enzymatiquement avec une ARN polymérase de nouvelle génération pour fabriquer de l'mRNA avec une contamination réduite par de l'ARN à double brin (dsRNA). Cela répond à un défi clé de l'industrie sans sacrifier les rendements.
Le poster, intitulé 'Réduction de la Contamination en dsRNA dans la Production d'mRNA à Haut Rendement', sera présenté le 30 juillet. Clay Shorrock, directeur exécutif du développement commercial chez LineaRx, a souligné que la réduction du dsRNA est une priorité absolue pour les développeurs de thérapies et les CDMO afin d'assurer une expression efficace de l'mRNA, de réduire les risques d'immunogénicité et de respecter la conformité réglementaire. La plateforme Linea IVT offre une solution entièrement enzymatique qui pourrait soutenir le développement de médicaments basés sur l'mRNA transformateurs, y compris les thérapies, les vaccins et les thérapies personnalisées.
Applied DNA Sciences (NASDAQ:APDN) wird seine Linea™ IVT-Plattform beim 4. jährlichen mRNA-basierten Therapeutik-Gipfel in Boston vom 29. bis 31. Juli 2024 präsentieren. Die Plattform kombiniert eine enzymatisch produzierte DNA-Vorlage mit einer RNA-Polymerase der nächsten Generation, um mRNA mit reduzierter Kontamination durch doppelsträngige RNA (dsRNA) herzustellen. Dies stellt eine zentrale Herausforderung der Branche dar, ohne die Erträge zu beeinträchtigen.
Das Poster mit dem Titel 'Reduktion der dsRNA-Kontamination bei der Hochleistungs-mRNA-Produktion' wird am 30. Juli präsentiert. Clay Shorrock, der Geschäftsleiter für Geschäftsentwicklung bei LineaRx, hob hervor, dass die Reduktion von dsRNA eine oberste Priorität für Therapeutik-Entwickler und CDMOs ist, um eine effiziente mRNA-Expression zu gewährleisten, Immunogenitätsrisiken zu verringern und die regulatorische Compliance sicherzustellen. Die Linea IVT-Plattform bietet eine vollständig enzymatische Lösung, die die Entwicklung transformativ wirkender mRNA-basierter Medikamente, einschließlich Therapien, Impfstoffen und personalisierten Therapien, unterstützen könnte.
- Linea IVT platform addresses industry-wide challenge of dsRNA contamination in mRNA production
- Platform maintains high yields while reducing dsRNA impurities
- Potential to support development of transformative mRNA-based medicines
- None.
- Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination -
STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination. View the poster here.
Details on the poster presentation are as follows:
Abstract and title: "Reduction of dsRNA Contamination in High-Yield mRNA Production"
Authors: Yuhua Sun, Huan Dong. Qiang Zhao, Finly Philip, Clay Shorrock, Aaron Chung, James A. Hayward
Date/Time: Tuesday, July 30, 2024, poster session from 3:45 - 4:30 p.m. (local time)
Clay Shorrock, executive director of business development with LineaRx, an Applied DNA Sciences company, stated, "Therapy developers and CDMOs in our Linea IVT sales pipeline unanimously cite dsRNA reduction as a workflow priority to ensure efficient mRNA expression, reduce the risk of undesired immunogenicity, and assure regulatory compliance. To date, the dsRNA challenge has been met with increased costs associated with purification and slower production times.
"Our poster at the Summit presents the Linea IVT platform as a fully enzymatic solution to an industry-wide challenge that can reduce the unwanted creation of double-stranded RNA (dsRNA) impurities within the IVT-mRNA synthesis process without sacrificing yields. We believe that Linea IVT supports the promise of mRNA and its potential to create a new generation of transformative medicines, such as mRNA therapeutics, vaccines, and personalized therapies."
About the Linea™ DNA and Linea™ IVT Platforms
The Linea DNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea™ RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.
About LineaRx
LineaRx, an Applied DNA Sciences, Inc. (NASDAQ: APDN) company, was formed in 2018 to commercialize the parent company's 20+ years of experience in polymerase chain reaction ('PCR')-based DNA manufacturing and leadership in enzymatic DNA production. To learn more about Linea™ DNA: click here
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, the unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, and Quarterly Report on Form 10-Q filed on February 8, 2024, and May 10, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts:
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
Program contact: Clay Shorrock, 631-912-6454, clay.shorrock@adnas.com
Web: www.adnas.com
Twitter: @APDN
SOURCE: Applied DNA Sciences
View the original press release on accesswire.com
FAQ
What is Applied DNA Sciences presenting at the 4th Annual mRNA-based Therapeutics Summit?
When and where is Applied DNA Sciences (APDN) presenting its poster on dsRNA reduction?
What are the key benefits of Applied DNA Sciences' (APDN) Linea IVT platform?
How does Applied DNA Sciences' (APDN) Linea IVT platform impact mRNA therapeutics development?
